Collateral for a security interest recorded Nov 10, 2014 (Redpath Equityholder Representative, LLC).
Term ends Mar 23, 2034 · High confidence
20-year base term ends Nov 27, 2033
Filed Nov 27, 2013 as application 14/092,036 · Granted May 17, 2016
Base term plus 116 days of patent term adjustment (USPTO delay)
Today
2013
2034
Clock starts
Nov 27, 2013
Nov 27, 2013
Term ends
Mar 23, 2034
Mar 23, 2034
Granted
May 17, 2016
May 17, 2016
base term
patent term adjustment
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
116
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
2 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
3
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 116 days past its 20-year base term on prosecution delay. 2 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 27, 2013, when this application, 14/092,036, was filed | Nov 27, 2033 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +116 days, USPTO patent term adjustment record | Mar 23, 2034 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 2 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Mar 23, 2034 | High confidence |
This family
| US 9,341,628 | this patent Mar 2034 | Mar 2034 |
| US 10,444,239 | In force Nov 2033 | Nov 2033 |
| Application 16/558,489 | Abandoned not computed | not computed |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 2, 2014 Reel 31875, frame 596 | Finkelstein, Sydney David; Jackson, Sara Ann; Bleicher, Jamie Michelle; Ellsworth, Eric Matthew Gayle; Smith, Dennis Morgan, JR. | Redpath Integrated Pathology, Inc. | Assignment of Assignor's Interest |
| Nov 6, 2014 Reel 34114, frame 658 | Redpath Integrated Pathology, Inc.; Redpath Acquisition Sub, Inc.; Interpace Diagnostics Corporation | Interpace Diagnostics Corporation | Merger and Change of Name |
| Nov 6, 2014 Reel 34118, frame 136 | Finkelstein, Sydney David; Jackson, Sara Ann; Bleicher, Jamie Michelle; Ellsworth, Eric Matthew Gayle; Smith, Dennis Morgan, JR. | Redpath Integrated Pathology, Inc. | Assignment of Assignor's Interest |
| Nov 10, 2014 Reel 34136, frame 312 | Interspace Diagnostics Corporation | Redpath Equityholder Representative, LLC | Security Interest |
| Nov 18, 2014 Reel 34202, frame 192 | Interpace Diagnostics Corporation | SWK Funding LLC, as Agent | Security Interest |
| Feb 22, 2016 Reel 37783, frame 678 | SWK Funding LLC | Interpace Diagnostics Corporation | Release of Security Interest |
| Sep 23, 2016 Reel 40125, frame 251 | Pdi, Inc.; Group Dca, LLC; Interpace Biopharma, LLC; Interpace Diagnostics, LLC; JS Genetics, Inc.; Redpath Acquisition Sub, Inc. | Redpath Equityholder Representative, LLC | Guarantee and Collateral Agreement |
| Sep 23, 2016 Reel 40127, frame 18 | Interpace Diagnostics Corporation; Pdi, Inc.; Group Dca, LLC; Interpace Biopharma, LLC; Interpace Diagnostics, LLC; JS Genetics, Inc. | Redpath Equityholder Representative, LLC | Joinder to Guarantee and Collateral Assignment |
| Mar 27, 2017 Reel 41754, frame 517 | Interpace Diagnostics Group, Inc. | Hudson Bay Master Fund Ltd. | Security Interest |
| Oct 20, 2021 Reel 57851, frame 289 | Interpace Diagnostics Corporation | Comerica Bank | Security Interest |
| Nov 2, 2021 Reel 57988, frame 110 | Interpace Biosciences, Inc.; Interpace Diagnostics Corporation; Interpace Diagnostics, LLC; Interpace Pharma Solutions, Inc. | Broadoak Fund V, L.p. | Security Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Mar 2034
Term ends Mar 23, 2034. Maintenance fees still fall due before then
Note
The 116 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2016 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.